Exploring all things genetics. Cambridge University Alumnus and current CEO of Sano Genetics Dr Patrick Short analyses the science, interviews the experts and helps share the stories of people who have been personally affected by genetic conditions. To take part in the latest research studies mentioned in this podcast please visit sanogenetics.com/research
This week on The Genetics Podcast, Patrick is joined by Madhuri Hegde, SVP and Chief Scientific Officer of Revvity. They discuss Revvity's advances in ultra-rapid clinical-grade sequencing, opportunities, challenges, and global inequities in newborn screening, and the dilemma of resequencing versus long-term data storage.Show Notes: 0:00 Intro to The Genetics Podcast00:59 Welcome to Madhuri01:52 Rebranding Revvity as a healthcare company02:51 Advancements in sequencing and Revvity's projects, including newborn screening tests and clinical ultra-rapid sequencing12:29 Opportunities and challenges for newborn sequencing and global inequity in access17:46 Price of sequencing and data storage versus resequencing considerations21:10 Complexities and nuances of genomic data interpretation23:28 Rethinking data portability and storage across the lifespan26:00 Understanding penetrance and population genetics through lifelong sequencing27:36 Scaling genetic counseling to match advancements and the potential value of chatbots32:45 The promise of proteomics and translating Olink data to the clinic 34:31 Implementing polygenic risk scores in clinical management 37:12 Transitioning from academia to industry and insights into product development38:37 Closing remarksFind out moreRevvity (https://www.revvity.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
This week on The Genetics Podcast, Patrick is joined by Dr. Euan Ashley, Chair of the Department of Medicine at Stanford, founder of various biotech companies, and author of The Genome Odyssey: Medical Mysteries and the Incredible Quest to Solve Them. They discuss Euan's groundbreaking work on ultra-rapid genome sequencing and how widespread sequencing, wearables, and AI could shape the future of preventive medicine and human performance.Show Notes: 00:00 Intro to The Genetics Podcast01:00 Welcome to Euan01:50 A pivotal case in Euan's career involving diagnosing a newborn experiencing cardiac arrest06:41 How Euan's team worked towards a record of eight hours from clinical sample to diagnosis10:05 Hurdles that need to be overcome before ultra-rapid sequencing workflows can be widely used in clinical settings11:40 Considerations around widespread genetic screening in newborns16:10 Weighing utility and uncertainty in genetic testing for disease19:17 Steps to a future where widespread genetic testing is economically viable 23:54 New frontiers of clinical genomics, including integration with electronic health records (EHRs) and wearables 28:24 The physiology and genetics of athletic performance and the inspiration behind the ELITE study33:54 Psychological drivers and effects of human performance37:57 Euan's interest in generative AI for developing novel therapies41:32 Closing remarks Find out moreThe Ashley Lab (https://ashleylab.stanford.edu/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
This week on The Genetics Podcast, Patrick is joined by Kent Rogers, Chief Executive Officer at EveryONE Medicines. They discuss Kent's journey across every side of the desk in the drug discovery space, EveryONE Medicines' efforts to develop antisense oligonucleotides for ultra-rare diseases, and the need to adapt regulatory models for n-of-1 therapies.Show Notes: 00:00 Intro to The Genetics Podcast00:59 Welcome to Kent and his experiences across every side of the pharma ‘desk'06:00 Challenges of commercialization for ultra-rare disease therapies and the advantage of antisense oligonucleotides (ASOs) 10:28 EveryONE Medicines' approach to regulatory bodies12:30 Regulatory feedback and expectations from EveryONE Medicines' platform-based approach to n-of-1 therapies15:47 Differences in regulatory requirements for rare disease across countries 19:53 Insights from being on different sides of the drug development industry22:40 Differences in healthcare systems across countries that can facilitate or impede drug development26:57 Rationale behind focusing on ASOs for treating rare diseases 28:03 Building EveryONE Medicines and Kent's approach to leadership33:20 Lessons from Kent's career37:17 Closing remarks Find out moreEveryONE Medicines (https://www.eomeds.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
This week on The Genetics Podcast, Patrick is joined by Matt Burgess, genetic counselor, host of the Demystifying Genetics podcast, and Adjunct Professor at Bay Path University. They discuss the evolution of genetic counseling, ethical challenges in gene therapy, and Matt's experiences with his podcast.Show Notes: 0:00 Intro to The Genetics Podcast00:59 Welcome to Matt02:09 Matt's run-ins with Olivia Newton John while working at Austin Hospital in Melbourne04:34 Matt's background and path to genetic counseling 06:58 The evolution of the field of genetic counseling over time and the role of counselors12:47 Matt's work on rare disease AP-4 hereditary spastic paraplegia (AP-4-HSP) and the ethical considerations of gene therapy20:22 Balancing the needs and expectations of individuals and families in counseling 23:06 Rebranding negative connotations of the word “counseling” 26:58 Memorable episodes from Matt's podcast Demystifying Genetics34:31 Differences in genetic counseling and healthcare in the US versus Australia and the UK40:00 Matt's current work on writing a novel, starting a company called Rosalind Genetics, and being involved in genetic education42:47 The potential and drawbacks of AI models in the context of genetic counseling and information46:46 Closing remarksFind out moreDemystifying Genetics (https://demystifying-genetics.buzzsprout.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
This week on The Genetics Podcast, Patrick is joined by Salvador Rico, Chief Medical Officer at Encoded Therapeutics. They discuss Salvador's journey into drug development, his work on gene therapy for X-linked myotubular myopathy, and fundamental challenges and exciting advances in the genetics field.Show Notes: 0:00 Intro to The Genetics Podcast00:59 Welcome to Salvador and how he became involved in drug development11:01 Frustrations and rewards of the genetics field13:59 Salvador's study on gene therapy for patients with X-linked myotubular myopathy (XLMTM)19:46 Risk of liver issues in gene therapy trials and attempts to mitigate them24:22 Encoded Therapeutics‘ approach to drug discovery and what motivated Salvador to join the team27:22 Steps towards therapeutic targeting of gene regulatory elements 30:04 Advantages of different methods for drug delivery 32:31 DNA- versus RNA-based therapy 34:56 Insights from approaches in other fields, including psychiatry36:35 Considerations for using natural history studies40:32 Expectations and goals for Encoded Therapeutics' current and upcoming studies43:17 Closing remarksFind out moreEncoded Therapeutics (https://encoded.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
This week on The Genetics Podcast, Patrick is joined by Leeland Ekstrom, CEO and co-founder of Nashville Bio. They discuss how Leeland went from being a consultant on a project for Vanderbilt University to a co-founder of a start-up and the unique aspects of NashBio's clinical and genetic database.Show Notes: 0:00 Intro to The Genetics Podcast00:59 Welcome to Leeland and the origin story of Nashville Bio05:13 Process of setting up NashBio's genome resource with 250K individuals11:52 How different pharmaceutical companies responded to NashBio's database and its unique advantages compared to others17:50 Key priorities for applications of the resource beyond target discovery20:19 The process of selecting additional gaps that NashBio's services can fill versus letting others fill them25:02 Advantages at Vanderbilt Medical Center that facilitated the project and how it can be replicated at other centers30:32 Immediate and long-term impacts of current NIH funding cuts on biotech and academia36:43 NashBio's current major focuses and future goals39:20 Closing remarksFind out moreNashBio (https://nashbio.com/)Press release: Alliance for Genomic Discovery completes 250,000 whole genomes to accelerate drug discovery (https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=b4b0c901-f8a2-4802-a4ef-b81167e24cfe) Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
This week on The Genetics Podcast, Patrick is joined by Sharon Terry, President & CEO of Genetic Alliance. They discuss how Sharon established a layperson-led biobank, her long-term work on rare diseases and patient advocacy, and her program to bring genetic technology to patients in low- to middle-income countries.Show Notes: 0:00 Intro to The Genetics Podcast00:59 Welcome to Sharon and a discussion of the personal experience with rare disease that started her journey03:47 Reasons why Sharon decided to establish the first layperson-led biobank05:34 Challenges with setting up the biobank infrastructure07:00 Balancing financial factors in a non-profit organization 09:30 Recent patterns and future insight into rare disease drug discovery framework and regulation15:32 Barriers to widespread collaboration and cooperation in rare disease research, and why it should be approached from a public health perspective18:12 Background and experiences from the iHope Genetic Health program in low- to middle-income countries24:44 Sharon's perspective on current challenges with the Genetic Information Non-discrimination Act28:49 Sharon's lessons learned in her patient advocacy and policy work, and her hopes for future legislation 33:04 Sharon's hopes for improved access to genetic testing and treatment for children in underserved communities34:34 How Sharon learned about rare diseases and genetics as a “homeschooling mom without a degree”37:54 Insights into how elements of spirituality can support advocacy work40:18 Closing remarksFind out moreGenetic Alliance (https://geneticalliance.org/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
This week on The Genetics Podcast, Patrick is joined by Dr. John Lepore, physician-scientist and CEO of ProFound Therapeutics. They discuss ProFound Tx's mission to expand the proteome to identify novel drug targets – which resulted in the ProFoundry atlas – and the ways in which John's diverse experiences inform his approach as a leader.Show Notes: 0:00 Intro to The Genetics Podcast00:59 Welcome to John02:01 John's background at GSK and his transition to drug discovery05:45 Establishing ProFound Therapeutics to expand the proteome and identify novel drug targets 08:27 Genomic origins of newly-identified proteins and the process of finding them09:49 Developing the ProFoundry atlas and integrating data across assays 15:27 Different approaches to inferring protein links and association to disease17:13 Collaboration with Pfizer to find regulators in the context of obesity18:04 Developing novel antibody-drug conjugates for cancer treatment20:27 Clarifying causality in proteomic data21:59 Approaching novel targets while considering industrial and business factors25:19 John's background as a cardiologist and how that impacts his current work27:26 Tips for biotech companies looking to be noticed by pharma for collaborations30:30 Considerations for investigating new and different therapeutic modalities and techniques33:39 How John consistently reinforces the translational angle as a business leader36:24 Closing remarks and future direction for ProFound TherapeuticsFind out moreProFound Therapeutics (https://www.profoundtx.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
This week on The Genetics Podcast, Patrick is joined by Raghib Ali, CEO, CMO, and Principal Investigator of Our Future Health UK. As a clinical epidemiologist with a passion for reducing health inequalities, Raghib offers fresh insights into the priorities, challenges, and transformative impact of the groundbreaking genomics initiative, Our Future Health. Show Notes: 0:00 Intro to The Genetics Podcast01:00 Welcome to Raghib and background on Our Future Health (OFH)03:57 Diseases that are a priority for OFH or are likely to benefit from its impact06:07 Challenges and opportunities for implementing change in the National Health Service (NHS), a partner of OFH, based on study findings09:20 Factors that contributed to the rapid recruitment of participants to OFH14:12 Efforts to ensure diversity of OFH participants and facilitate accessibility for all16:35 Why OFH chose to use arrays for genomic profiling18:57 Navigating the obstacles and opportunities in public and private partners22:28 Strengths and weaknesses of the medical record system in the UK 25:54 Efforts to rapidly provide results from OFH and integrating other datasets and techniques in the future28:43 Raghib's unique educational and training journey 31:49 The importance of evaluating components beyond genetics for a full picture of health33:28 Aims and findings of the first prospective cohort study in the UAE35:26 The potential contribution of epigenetic inheritance to disease risk 37:43 How Raghib overcame adversity early in life40:56 Closing remarks Find out moreOur Future Health (https://ourfuturehealth.org.uk/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
This week on The Genetics Podcast, we're celebrating Rare Disease Day with a very special episode. Patrick is joined by clinical nephrologist Anthony Bleyer and geneticist Stan Kmoch to discuss how their decade-long international collaboration has uncovered genetic mutations in families with rare inherited kidney diseases – including Patrick's.Show Notes: 0:00 Intro to The Genetics Podcast00:59 Welcome to Anthony and Stan02:05 The origin story for Anthony and Stan's long-distance collaboration06:55 Stan's background in metabolic disorders and sequencing techniques11:09 Common genetic culprits and barriers to identifying mutations that cause kidney disease14:01 Background and findings from Anthony and Stan's ApoA4 study23:54 Potential therapeutic avenues based on the ApoA4 study26:49 Current and future focuses for characterizing diseases in families30:42 Working with collaborators internationally to access large databases and registries33:05 Innovative transplant methods, including genetically-modified pig kidneys 36:36 Closing remarks and a heartfelt thank you to researchers and families driving rare disease researchFind out more Latest study: https://doi.org/10.1016/j.kint.2023.11.021Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
This week on The Genetics Podcast, Patrick is joined by Michelle Werner, CEO at Alltrna and CEO/Partner at Flagship Pioneering. They discuss Alltrna's promising findings from its first preclinical study on using tRNA to rescue stop codon disease, the strategic use of basket trials, and more!Show Notes: 0:00 Intro to The Genetics Podcast01:00 Welcome to Michelle02:13 Overview of Alltrna's aims and the advantages of using tRNA to tackle stop codon disease5:27 Using basket trials for genetic diseases08:03 Highlights from Alltrna's first preclinical study using tRNA to restore protein production to clinically meaningful levels in methylmalonic acidemia (MMA) and phenylketonuria (PKU)14:02 Considerations in delivery techniques and Alltrna's use of nanoparticles19:22 Stability of tRNA and how engineered tRNAs are recognized in vivo 23:12 Strategic design of basket trials and diseases that are covered26:16 Adaptive trial design in the rare genetic disease setting28:15 Michelle's experience with regulatory organizations on new approaches to trial design32:14 Insights from spearheading Alltrna and Flagship Pioneering's innovative approaches 37:26 Michelle's lessons from working in big pharma versus a small biotech start-up40:50 Closing remarks and a call for collaboratorsFind out more Alltrna (https://www.alltrna.com/)Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
On this week's episode of The Genetics Podcast, we're joined by Jocelynn Pearl, Director of Cancer Cell Therapy at the TAM Center, host of the Lady Scientist Podcast and Co-Founder of LabDAO. Patrick and Jocelynn discuss her move to Mexico to help accelerate the development of new cancer therapies, harnessing the power and potential of decentralized science, and overcoming sky-high gene therapy costs to increase accessibility for patients.Show Notes: 0:00Intro to The Genetics Podcast01:00Welcome to Jocelynn02:03 Jocelynn's past work at The Institute for Systems Biology 04:55 How Jocelynn approached her transition to biotech from the world of academia10:14 Exploring decentralized science, including how it works and Jocelynn's involvement to date15:54 What a Decentralized Autonomous Organisation (DAO) is and how this type of organizational structure supports scientific development22:45 The “fast grant” surge and other non-traditional funding methods28:00 Hosting the Lady Scientist Podcast and some of Jocelynn's favorite moments32:43 Jocelynn's move to Mexico to serve as Director of Cancer Cell Therapy at the TAM Center36:12 The biggest differences between building out drug development programs in Mexico and the US38:31 Regulatory differences between countries in the context of stem cell therapies42:48 The advantages for cancer therapeutic development in Jocelynn's current environment46:20Driving down the costs of gene therapies and the impact on accessibility 48:09 Closing remarksFind out moreLabDAO:https://www.lab.bio/ Please considerrating and reviewing us on your chosen podcast listening platform!https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj
Summary: This week on The Genetics Podcast, Patrick is joined by Eric Adler, Chief Medical Officer and Head of Research at Lexeo Therapeutics and Professor of Medicine at University of California San Diego. Eric shares his experience with genetic cardiomyopathy and his work on gene therapy for Danon disease, drawing from both clinical and research perspectives. Additionally, he explores the evolution of the field and the broader challenges faced by cardiovascular patients. Show Notes: 0:00 Intro to The Genetics Podcast 01:00 Welcome to Eric and his efforts in cardiomyopathy at the bench and bedside 03:32 How modeling genetic diseases using pluripotent stem cells lead Eric to studying Danon disease 04:50 Pivoting from basic to translational research using adeno-associated viruses (AAV)-based gene therapy 07:58 Uncovering genetic cardiomyopathies that were misdiagnosed as idiopathic cardiomyopathy 09:55 Treatment, screening, and penetrance of Danon disease 12:30 Recent successes and remaining challenges in cardiovascular disease 19:47 Battling distrust in the medical profession 21:55 Preventative therapy using APOE2 for patients at risk of early Alzheimer's 25:15 Motivations behind and advantages of Eric's patient-centered approach to therapeutics 27:24 Balancing regulatory requirements for protocols versus patient needs 29:49 The importance of committed clinical partners for successful trial execution 36:08 Eric's passion for cooking and how he won a cooking competition 39:02 Closing remarks and Lexeo Therapeutics' aims for 2025 Find out more Lexeo Therapeutics (https://www.lexeotx.com/) Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
This week on The Genetics Podcast, Patrick is joined by Versha Pleasant, Clinical Assistant Professor in the Department of Obstetrics and Gynecology, University of Michigan and Director of the Cancer Genetics and Breast Health Clinic at Von Voigtlander Women's Hospital. They discuss ongoing disparities in healthcare, in particular why black women in the US have a 40% higher chance of dying from breast cancer than white women, the impact of the US Educate Act on equality, diversity and inclusion education, and much more. 00:00:00 – Intro to The Genetics Podcast 00:01:52 – Welcome to Versha 00:03:22 – How black women have a 40% higher chance of mortality from breast cancer than white women, and the biggest drivers of this disparity 00:07:09 – Multifaceted approaches to addressing disparities 00:09:10 – Racial health duplicity and increasing access to genetic testing and mammography for black women 00:13:51 – The challenges of using precision medicine to stratify risk in black communities and historical harms in US medical research 00:14:29 – How to design for inclusive studies that effectively represent communities of colour 00:16:13 – Considering universal genetic testing and counseling for black women 00:21:24 – The logistics of making universal testing a reality, and the importance of community education and trust building 00:27:18 – What Versha is focused on next and the big topics she wants to tackle 00:33:24 – The role of community education and diversifying modes of communication for knowledge sharing 00:34:36 – Versha's perspectives on the US Educate Act and the impact it could have on what doctors of the future are taught 00:40:52 – Versha's advice to people who would like to pursue a similar career in medicine 00:43:28 – Where Patrick sees genetics evolving in the next ten years and his vision for the future of The Genetics Podcast 00:47:39 – Closing remarks Find out more Universal Genetic Counseling and Testing for Black Women: A Risk-Stratified Approach to Addressing Breast Cancer Disparities: https://www.clinical-breast-cancer.com/article/S1526-8209(24)00338-0/fulltext Please consider rating and reviewing us on your chosen podcast listening platform! https://drive.google.com/file/d/1Bp2_wVNSzntTs_zuoizU8bX1dvao4jfj/view?usp=share_link
This week on The Genetics Podcast, Patrick is joined by Jonathon Hill, associate professor at Brigham Young University and co-founder and VP of Wasatch Biolabs. Jonathan and Patrick discuss the power of long-read sequencing, how Wasatch Biolabs was created, and how Jonathon has fostered valuable collaborations between academic labs and Wasatch Biolabs.
This week on The Genetics Podcast, Patrick is joined by Angela Bradshaw, Director for Research at Alzheimer Europe and honorary lecturer at the University of Glasgow. Patrick and Angela discuss coordinating the dementia research efforts of more than 30 countries, the enormous heterogeneity of dementia and Alzheimer's disease, the future of potential new gene therapies, and the critical role of advocacy organizations for patient communities.
This week on The Genetics Podcast, we're joined by Hilary Martin, Group Leader in Human Genetics at the world-renowned Wellcome Sanger Institute. Hilary and Patrick discuss her group's work on neurodevelopmental conditions, the role of common genetic variants in rare disease, and how to untangle the impact of direct and indirect genetic influences on various traits. Find out more Nature paper: Examining the role of common variants in rare neurodevelopmental conditions https://www.nature.com/articles/s41586-024-08217-y Genes and Health Project https://www.genesandhealth.org
Happy New Year! In our first episode of 2025, Patrick is joined by Erik Ingelsson, Chief Scientific Officer at Wave Life Sciences. Erik is also the formerr Senior Vice President of Target Discovery at GlaxoSmithKline and a former Professor at Stanford and Uppsala universities. Patrick and Erik discuss Wave's world-first discovery in RNA editing therapies for Alpha-1 Antitrypsin Deficiency (AATD), Erik's far-reaching career across academia, big pharma and biotech, and how to be a present parent in the thick of a thriving career.
Join us as we welcome back Dr. Veera Rajagopal, a discovery scientist at Regeneron with an interest in human genetics and drug target discovery in neuroscience and psychiatry. If you're a regular listener, you may be familiar with Veera's quarterly appearances on the show, where Patrick and he discuss the latest developments in genetics, drug discovery, and precision medicine. Grab yourself a cup of something warm and tune in as Veera and Patrick close out 2024 with a wrap up covering: Population genomics programs New Alzheimer's research The impact of genetics on menopause onset Newborn genetic screening Tune in now, and don't forget to check out Veera's substack, GWAS Stories, and his Twitter, @doctorveera.
This week we're joined by Eric Green, Founder and CEO of Trace Neuroscience, Co-Founder and Chief Scientific Officer at Maze Therapeutics, and Adjunct Clinical Assistant Professor at Stanford University School of Medicine. Eric and Patrick discuss Eric's transition from cardiology to the world of entrepreneurship, the role of highly focused biotechs in creating precision therapies, and the development of high-impact gene therapies for people with amyotrophic lateral sclerosis (ALS).
In this episode, we're joined by Dr. Ness Bermingham, Operating Partner at Khosla Ventures and Chair of the Board at Korro Bio. A scientist-turned-biotech entrepreneur, Ness is passionate about the power of science to tackle some of healthcare's biggest challenges. Ness co-founded Intellia Therapeutics, a leader in CRISPR gene editing, and Korro Bio, an innovator in RNA editing, driving breakthroughs that translate cutting-edge science into real healthcare solutions. With over 20 years of experience in biotech and healthcare, he's played a vital role in shaping startups into companies that develop life-changing medicines. Tune in as we dive into Ness's journey and his insights on innovation in biotech!
Welcome back to The Genetics Podcast! Today, we're joined by Dr. Luis Diaz, Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering and a White House Appointee to the National Cancer Advisory Board. Dr. Diaz's career has been defined by his commitment to translating cutting-edge cancer genomics into clinical practice. In this episode, he and Patrick dive into his groundbreaking trial on mismatch repair (MMR)-deficient rectal cancer, along with his pioneering work on liquid biopsies, immunotherapies targeting tumors with microsatellite instability, and advancements in precision oncology. To learn more about Dr. Diaz and his work, visit his research page here: https://www.mskcc.org/research-areas/labs/luis-diaz.
On this week's episode, we're joined by Susan Liebman, Research Professor at University of Nevada, Reno School of Medicine and author of a new family memoir rooted in genetics called The Dressmaker's Mirror. Susan reflects on the deeply personal loss of her niece to an undiagnosed genetic condition, offers her insights on genetic screening for at-risk individuals and populations, and provides valuable advice for early career scientists.
Summary: This week, Patrick is joined by Jim Wilson, Professor of Human Genetics at the University of Edinburgh. Jim discusses the genetics of isolated populations and the Vikings Genes project, which has led him to work with communities from more than 25 Scottish islands, and how new sequencing programs can dramatically improve health outcomes for these groups. He also touches on mapping Prince William's mitochondrial DNA, lobbying Westminster to raise awareness of genetic screening, and his Irish Film & Television Awards (IFTA) winning work with the Irish Traveller community.
In this week's episode, Patrick is joined by Michelle Teng, CEO and Co-Founder of Etcembly Ltd and Founding Executive Director and Chief Scientific Officer of SynaptixBio. Michelle explains how her team is training large language models (LLMs) to analyze immune system data and how the company's Long Term Survivor Study is helping identify T-cell profiles associated with sustained cancer remission. She also speaks to her own experience of ultra-rare genetic disease.
In this episode, we welcome Dr. Eric Fauman, Executive Director and Head of Computational Biology in the Internal Medicine Research Unit at Pfizer. Eric and Patrick discuss facilitating efficient identification of potential drug targets and the role of artificial intelligence in genetics research and drug discovery. Please note that Eric has kindly shared some interesting research that was mentioned in the podcast. It is pasted at the end of the show notes.
In this episode, we're joined by Noam Baumatz, CEO and Co-Founder of Noga Therapeutics, a company dedicated to developing gene therapies for rare and severe diseases through engineering macrophages. Motivated by his highly personal experience of rare disease, Noam founded Noga to develop the type of gene therapies his daughter was unable to access. He and Patrick discuss his work with parents and families affected by rare disease, the road to effective, financially accessible gene therapies, and Noam's previous work in traditional Chinese medicine.
Join us as we welcome back Dr. Veera Rajagopal, a discovery scientist at Regeneron with an interest in human genetics and drug target discovery in neuroscience and psychiatry. If you're a regular listener of The Genetics Podcast, you may be familiar with Dr. Veera's annual round-up episodes, and more recently, his quarterly appearances on the show. We're pleased to bring you the latest quarterly roundup, during which Dr. Veera and Patrick walk through the most recent developments in genetics, drug discovery, and precision medicine. In this episode, Dr. Veera and Patrick dive into a wide variety of topics, including: - The evolution of skin color in humans - The potential of a novel tau isoform for Alzheimer's treatment - Protective mechanisms of tomoregulin-1 against herpes simplex virus - The discovery of a new noncoding Mendelian disease mechanism linked to cardiac arrhythmias - A comparative analysis of whole genome versus whole exome sequencing for gene discovery. Tune in now, and don't forget to check out Veera's substack, GWAS Stories, and his Twitter, @doctorveera. Additionally, we're excited to invite you to an in-person meetup for The Genetics Podcast during the ASHG Annual Meeting in Denver, CO! Over the years, we've had the honor of speaking with leading voices across science, industry, patient advocacy, and policy. Now, we're bringing this incredible community together face-to-face. Join us on the evening of Thursday, November 7. To RSVP, visit: https://lu.ma/geneticspodASHG.
In this episode, Patrick speaks with Mark Taylor, Head of Strategic Partnerships at LGC Group, about bridging the gap between genomics innovation and equitable healthcare. They discuss Mark's work with the National Institute for Health Research (NIHR), challenges in scaling precision therapies for the NHS, and strategies for engaging underrepresented populations. Additionally, we're excited to invite you to an in-person meet up for The Genetics Podcast during the ASHG Annual Meeting in Denver, CO! Over the years, we've had the honor of speaking with leading voices across science, industry, patient advocacy, and policy. Now, we're bringing this incredible community together face-to-face. Join us on the evening of Thursday, November 7. To RSVP, visit: https://lu.ma/geneticspodASHG.
Join us at our first in-person podcast event! We will be hosting a reception during the ASHG Annual Meeting in Denver, CO. The event will be held on the evening of Thursday 7 November. Please submit your information in this form (https://lu.ma/geneticspodASHG) to signify your interest in attending!
This week Patrick is joined by Paul Wille, Director of Product Development at Abeona Therapeutics. They discuss the use of adeno-associated virus (AAV) as a vector for gene therapy delivery, outline its limitations and benefits, and hone in its potential in the context of genetic eye disorders. Paul also shares his journey from academia to industry and emphasizes the importance of building on existing technologies to advance the field. Additionally, please consider joining us at our first in-person podcast event! We will be hosting a reception during the ASHG Annual Meeting in Denver, CO. The event will be held on the evening of Thursday 7 November. Please submit your information in this form (https://lu.ma/geneticspodASHG) to signify your interest in attending!
In this episode, Dr. Mike Snyder, Director of the Center for Genomics and Personalized Medicine at Stanford School of Medicine, shares his pioneering work on health monitoring using multiomics and wearables. The conversation spans personalized aging, the challenges of implementing precision medicine in mainstream healthcare, and Dr. Snyder's vision for a future where proactive health monitoring predicts illness before symptoms appear, keeping people healthier longer. Tune in for a fascinating episode centered on preventative medicine!
This week, Patrick welcomes President and CEO of The Jackson Laboratory, Lon Cardon. They discuss the rise of genome-wide association studies (GWAS) and how they changed the face of genetics research and why Lon took the plunge and moved from academia to industry in an era when it was an unpopular choice. Plus, they cover the future of disease taxonomy and why data sharing remains vital to the field of genetics.
This week, we're thrilled to welcome Nadav Ahituv, the Director of the Institute of Human Genetics at the University of California, Berkeley. Patrick and Nadav discuss his research on gene regulation, including his intriguing work on bats and their unique metabolic adaptations – and what that means for human health. They also discuss the evolution of our understanding of genetics, from ancient DNA insights to the mechanisms driving human traits, and how these discoveries could pave the way for future therapies.
In this episode Patrick is joined by Marco Quarta, Co-founder and CEO of Rubedo Life Sciences, and previously Director of Bioengineering in Stem Cells and Regenerative Medicine at Stanford University. Since childhood Marco had the dream of ‘curing' ageing and his work at Rubedo focuses on understanding cell senescence, with the goal of developing novel therapies for age-linked diseases. Join Marco and Patrick as they discuss his transition from academia to founding multiple companies, why not all senescent cells are equal, and how understanding the processes behind cell ageing could help extend human healthspan.
In this episode, we're joined by Martin Borch Jensen, Co-Founder and Chief Scientific Officer at Gordian Biotechnology and President of Norn Group, a non-profit dedicated to accelerating research and development of therapies targeting the biology of ageing. Patrick and Martin discuss the phenomenon known as the “ageing problem,” how understanding biological age could crack the code on age-related diseases, and the challenges of building a company in a field with no business model blueprint.
In this episode, we're joined by Tony Cox, CEO of UK Biocentre. After spending more than 20 years at The Wellcome Sanger Institute, where he worked on the Human Genome Project, Tony moved to UK Biocentre in January 2020 – just before the world was turned upside down by the COVID-19 pandemic. The organization pivoted to play a key role in the UK's response effort, and under Tony's leadership the center sequenced 33 million DNA samples in just two years. Patrick and Tony discussed receiving a phone call from the UK government, scaling from sequencing 1,000 to 100,000 samples per day, and how to manage producing five tonnes of cardboard waste on a daily basis.
This week, we welcome Dr. Mike Gaziano, professor of medicine at Harvard Medical School and the Director of the Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC). Mike is also one of two Principal Investigators of the Million Veteran Program - a national research project in the US looking at how genes, lifestyle, military experiences, and exposures affect health and wellness in veterans. This is a huge undertaking, as Mike describes this project as “the largest health system-based mega-biobank in the world". Join Patrick and Dr. Mike for a discussion on the Million Veteran Program's research, its integration of extensive data from veterans, and its role in shaping the future of personalized medicine for the veteran community.
This week, we're joined by Scott Weiss, the Professor of Medicine at Harvard University, Associate Director of the Channing Division of Network Medicine at the Brigham and Women's Hospital, and former Scientific Director at Partners HealthCare Personalized Medicine at Mass General Brigham. Patrick and Scott discuss the challenges of integrating large-scale, longitudinal multi-omic profiling into healthcare settings, demonstrating the value of preventative initiatives to health insurance providers, and why, at 78, Scott isn't planning on retiring from genetics anytime soon.
This week Patrick is joined by Austin Argentieri, Research Fellow at Harvard Medical School, Affiliate Member of the Broad Institute of MIT and Harvard, and Research Fellow at Massachusetts General Hospital. Austin's work focuses on the proteomics of aging and how proteomic signatures are highly predictive for estimating biological age. From the potential of therapeutic applications, to why no “fountain of youth” genes have yet been identified, he and Patrick discuss the heritability of aging and how proteomics can help identify risk of age-related disease.
In this episode, we're joined by Daniel O'Connor, Director of Regulatory Policy and Early Access at The Association of the British Pharmaceutical Industry. Daniel previously spent almost 18 years at the Medicines and Healthcare products Regulatory Agency (MHRA) and over his career has specialized in improving and incentivizing pathways to rare disease treatment development. Join Patrick and Daniel as they discuss orphan drug designation, the importance of international collaboration, and how unlocking new regulatory approaches to preventative medicine can help change the future of rare and ultra-rare conditions.
Join us as we welcome back Dr. Veera Rajagopal, a discovery scientist at Regeneron with an interest in human genetics and drug target discovery in neuroscience and psychiatry. If you're a regular listener of The Genetics Podcast, you are likely familiar with Dr. Veera's annual round-up episodes. This year, we are excited to announce quarterly episodes with Dr. Veera, where he and Patrick walk you through the latest developments in genetics, drug discovery, and precision medicine throughout the year. This quarter's episode will dive into the discovery of a recurrent de novo mutation in a noncoding region linked to neurodevelopmental disorders, the role of RAB32 in Parkinson's disease (PD), insights into monogenic conditions like systemic lupus erythematosus, and new perspectives on Alzheimer's genetics. Tune in now, and don't forget to check out Veera's substack, GWAS Stories, and his Twitter, @doctorveera.
This week, we're joined by Jakob Steinfeldt, Co-Founder and Chief Scientific Officer at Pheiron, and Honorary Research Fellow at University College London. Jakob and his team are working to create the ‘GPS' for drug development, using causal insights to identify highly-informed drug targets, with the aim of accelerating clinical trials and revolutionising researchers' ability to classify highly-relevant patients. Join Patrick and Jakob as they discuss the transition from academia to the world of start-ups, exactly why machine learning has so much potential, and how Pheiron is utilising human data to help get high-impact treatments to patients faster.
Welcome to The Genetics Podcast, where Patrick interviews Dr. Andrea Gropman, Professor of Pediatrics and Neurology at George Washington University School of Medicine and Health Sciences and Chief of Neurogenetics at Children's National Hospital. This conversation explores Dr. Gropman's extensive expertise in genetics and how its integration into clinical settings can optimise patient outcomes. We'll also discuss the importance of interdisciplinary collaboration, regulatory and ethical considerations, and the future of genetic research. Tune in for an interesting discussion on the transformative impact of genetics on contemporary medical practice and practical clinical applications.
This week, we welcome Lori Orlando, Associate Professor of Medicine and Director of the Precision Medicine Program in the Center for Applied Genomics and Precision Medicine at Duke University. Lori discusses her work as a health services researcher, the MeTree family health history platform, and how she and her team are working to develop a sustainable model for bringing genomic medicine into primary care.
This week, we're joined by Ben Goldacre, a renowned doctor, academic, author, and journalist. His books include “Bad Science” and “Bad Pharma,” among others, and he is currently a Professor of Evidence-Based Medicine at University of Oxford. There, he runs the Bennett Institute for Applied Data Science which aims to pioneer the better use of data, evidence and digital tools in healthcare and policy. Patrick and Ben discuss Join Patrick and Ben for an open conversation about Ben's choice to step back from the public eye and the power of the OpenSAFELY platform to improve security, transparency and analysis of Electronic Health Records.
This week, we welcome Michelle Werner, CEO of Alltrna and CEO/Partner at Flagship Pioneering. Michelle and her team are working at the cutting-edge of tRNA therapies, which they hope will present a scalable treatment method for people in the rare and ultra-rare disease communities. Join Patrick and Michelle for an exciting conversation about this breakthrough technology, from the transferable potential of this new modality across stop codon diseases, to Michelle's personal passion for delivering workable solutions to the rare disease community.
In this episode, we welcome Dr. Almut Heinken, Junior Professor at the INSERM Institute of Nutrition, Genetics, Environment, and Risk Exposure at Université de Lorraine. Her work focuses on multiscale metabolic modelling of host-microbiome interactions and their role in human health. She has contributed to the development of genome-scale reconstructions of human microbes, known as the AGORA resource. Almut has also developed tools to build personalised microbiome models and applied these models to inflammatory bowel disease, Parkinson's Disease, and colorectal cancer. She is currently working on modelling the interactions between diet, the microbiome, and the epigenome. Tune in to this exciting discussion!
Join us in welcoming Mavis Machirori, Senior Researcher at the Ada Lovelace Institute and co-founder of Genetics Engage (https://www.geneticsengage.org/)! With over 10 years of clinical experience as a midwife, Mavis is dedicated to promoting social justice in healthcare. Her research focuses on the impact of new healthcare technologies on social inequalities. Passionate about equity in data and genomics, she addresses the broader societal impacts of these advancements. Mavis was a guest on our Participant Diversity webinar in 2020, and we are thrilled to have her back on The Genetics Podcast at Sano!
Join us in welcoming back a familiar voice, Allison Watson, to The Genetics Podcast. We first spoke to Allison on the podcast back in October 2019 about her work in ring chromosome 20 syndrome (also known as r(20) syndrome). Allison is the Co-founder and CEO of Ring 20 Research and Support UK CIO, a patient advocacy organisation focused on awareness and research for ultra rare r(20) syndrome epilepsy. Tune in as she tells us about developments in the advocacy space for r(20) syndrome over the past four years and landmark moments for research into the condition.v
Welcome to Episode 135 of The Genetics Podcast, where we welcome Dr. Ingrid Holm, an Associate in Medicine at Boston Children's Hospital and a Professor of Pediatrics at Harvard Medical School. Ingrid is passionate about integrating newborn screening programs to healthcare systems. She was the co-investigator on the original BabySeq study and is now co-leading a new study — BabySeq2: Bringing equity to genomic sequencing in newborns. She also leads pioneering work in a range of other paediatric projects, all of which we discuss in this episode!